It has been previously reported that RAS-like and BRAF-like thyroid cancers can activate the metabolic pathway and cell adhesion molecule/extracellular matrix receptor interaction pathways, respectively [19], consistent with our observation. This evidence concerns the gene BRAF and thyroid gland carcinoma.